| 英文名稱 |
中文名稱 |
CAS號(hào) |
操作 |
| Cefixime Impurity 15 |
7-氨基-3-氯-3-頭孢烯-4-羧酸對(duì)硝基芐基酯鹽酸鹽(RC) |
53483-70-8 |
詳細(xì)
|
| Valproate Sodium EP Impurity D |
丙戊酸鈉雜質(zhì)D |
52061-75-3 |
詳細(xì)
|
| Valproate Sodium EP Impurity I |
2-丙基戊腈 |
13310-75-3 |
詳細(xì)
|
| Valproate Sodium Impurity 8 |
丙戊酸鈉雜質(zhì)8 |
|
詳細(xì)
|
| Valproate Sodium EP Impurity J |
丙戊酸鈉雜質(zhì)J |
5340-48-7 |
詳細(xì)
|
| Valproate Sodium Impurity 6 |
丙戊酸鈉雜質(zhì)14 |
258264-00-5 |
詳細(xì)
|
| Valproate Sodium EP Impurity F |
丙戊酰胺 |
2430-27-5 |
詳細(xì)
|
| Valproate Sodium Impurity 10 |
丙戊酸鈉雜質(zhì)10 |
|
詳細(xì)
|
| Valproate Sodium EP Impurity K |
|
|
詳細(xì)
|
| Valproate Sodium Impurity 20 |
2-丙基己酸 |
3274-28-0 |
詳細(xì)
|
| Omeprazole Impurity 18 |
2-氯甲基-4-氯-3,5-二甲基吡啶鹽酸鹽 |
143016-68-6 |
詳細(xì)
|
| Omeprazole Impurity 15 |
2-氯甲基-4-氯-3,5-二甲基吡啶 |
142885-96-9 |
詳細(xì)
|
| Omeprazole Impurity 14 |
4-甲氧基-2,3,5-三甲基吡啶氮氧化物 |
86604-80-0 |
詳細(xì)
|
| Omeprazole Impurity L |
2-(乙酰氧基甲基)-4-甲氧基-3,5-二甲基吡啶 |
91219-90-8 |
詳細(xì)
|
| Omeprazole Impurity 21 |
4-甲氧基-2-硝基乙酰苯胺 |
119-81-3 |
詳細(xì)
|
| Omeprazole Impurity 22 |
4-甲氧基鄰苯二胺 |
102-51-2 |
詳細(xì)
|
| Omeprazole Impurity 19 |
4-甲氧基-2,3,5-三甲基吡啶 |
109371-19-9 |
詳細(xì)
|
| Omeprazole Impurity 20 |
1H-Benzimidazole, 5-methoxy-1-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]- |
1346600-29-0 |
詳細(xì)
|
| Omeprazole Impurity 24 |
3,5-二甲基-4-硝基吡啶 1-氧化物 |
14248-66-9 |
詳細(xì)
|
| Omeprazole Impurity 23 |
2,3,5-三甲基吡啶氧化物 |
74409-42-0 |
詳細(xì)
|
| Omeprazole Impurity 25 |
(R)-奧美拉唑 |
119141-89-8 |
詳細(xì)
|
| Bedaquiline Impurity 3 |
Bedaquiline Impurity 14 |
654654-93-0 |
詳細(xì)
|
| Bedaquiline Impurity 2 |
3-芐基-2-甲氧基喹啉 |
1381767-10-7 |
詳細(xì)
|
| Bedaquiline Impurity 1 |
貝達(dá)喹啉雜質(zhì) |
861709-47-9 |
詳細(xì)
|
| Esomeprazole Impurity I |
埃索美拉唑雜質(zhì)I |
158812-85-2 |
詳細(xì)
|
| Omeprazole Impurity 17 |
2-氯甲基-3,5-二甲基-4-硝基吡啶 |
153476-68-7 |
詳細(xì)
|
| Esomeprazole Impurity J |
（S）-4-去甲氧基-4-氯奧美拉唑 |
863029-89-4 |
詳細(xì)
|
| Omeprazole Impurity K |
4-硝基-2,3,5-三甲基吡啶-N-氧化物 |
86604-79-7 |
詳細(xì)
|
| Omeprazole Impurity 27 |
4-羥基奧美拉唑 |
301669-82-9 |
詳細(xì)
|
| 5-O-Desmethyl Omeprazole |
5-O-去甲基奧美拉唑 |
151602-49-2 |
詳細(xì)
|
| Omeprazole Impurity E |
奧美拉唑 N-氧化物 |
176219-04-8 |
詳細(xì)
|
| Omeprazole Impurity F |
奧美拉唑EP雜質(zhì)F |
125656-82-8 |
詳細(xì)
|
| Omeprazole Impurity G |
奧美拉唑EP雜質(zhì)G |
125656-83-9 |
詳細(xì)
|
| Omeprazole Impurity J |
2-氯甲基-3,5-二甲基-4-甲氧基吡啶鹽酸鹽 |
86604-75-3 |
詳細(xì)
|
| Omeprazole Impurity D |
奧美拉唑雜質(zhì)A |
88546-55-8 |
詳細(xì)
|
| Esomeprazole Impurity C |
奧美拉唑硫醚 |
73590-85-9 |
詳細(xì)
|
| Omeprazole Impurity B |
埃索美拉唑雜質(zhì)B |
110374-16-8 |
詳細(xì)
|
| Tofacitinib Impurity 6 |
4-氯吡咯并嘧啶 |
3680-69-1 |
詳細(xì)
|
| Dapagliflozin Impurity G |
達(dá)格列凈雜質(zhì)B |
2169998-23-4 |
詳細(xì)
|
| Dapagliflozin Impurity 10 |
達(dá)格列凈雜質(zhì)14 |
2271248-78-1 |
詳細(xì)
|
| Dapagliflozin Dimer |
達(dá)格列凈二聚體 |
|
詳細(xì)
|
| Dapagliflozin Impurity 12 |
(5-碘-2-氯苯基)(4-乙氧基苯基)甲酮 |
1103738-26-6 |
詳細(xì)
|
| Dapagliflozin Impurity 4 |
(2S,3R,4R,5S,6R)-2-(4-氯-3 - ((4-乙氧基苯基)(羥基)甲基)苯基)-6 |
1204222-85-4 |
詳細(xì)
|
| Dapagliflozin alfa-Isomer |
達(dá)格列凈雜質(zhì)G |
1373321-04-0 |
詳細(xì)
|
| Cefixime EP Impurity B |
頭孢克肟雜質(zhì)B |
1335475-19-8 |
詳細(xì)
|
| Cefixime Impurity A |
頭孢克肟雜質(zhì)A |
1614255-90-1 |
詳細(xì)
|
| Tofacitinib Impurity 68 |
托法替尼雜質(zhì)68 |
|
詳細(xì)
|
| Tofacitinib Impurity 67 |
托法替尼雜質(zhì)67 |
|
詳細(xì)
|
| Tofacitinib Impurity 69 |
托法替尼雜質(zhì)69 |
|
詳細(xì)
|
| Tofacitinib Impurity 70 |
托法替尼雜質(zhì)70 |
|
詳細(xì)
|
| Tofacitinib Impurity 71 |
托法替尼雜質(zhì)71 |
|
詳細(xì)
|
| Tofacitinib Impurity 72 |
托法替尼雜質(zhì)72 |
|
詳細(xì)
|
| Tofacitinib Impurity 73 |
托法替尼雜質(zhì)73 |
|
詳細(xì)
|
| Tofacitinib Impurity 74 |
托法替尼雜質(zhì)74 |
|
詳細(xì)
|
| Tofacitinib Impurity 75 |
3-氨基-4-甲基吡啶 |
3430-27-1 |
詳細(xì)
|
| Tofacitinib Impurity 66 |
(3S,4S)-1-芐基-N,4-二甲基哌啶-3-胺 |
477600-69-4 |
詳細(xì)
|
| Tofacitinib Impurity 79 |
托法替尼雜質(zhì)79 |
|
詳細(xì)
|
| Tofacitinib Impurity 80 |
托伐替尼雜質(zhì)80 |
|
詳細(xì)
|
| Tofacitinib Impurity 82 |
托法替尼雜質(zhì)82 |
|
詳細(xì)
|
| Tofacitinib Impurity 83 |
托法替尼雜質(zhì)83 |
|
詳細(xì)
|
| Tofacitinib Impurity 84 |
托法替尼雜質(zhì)84 |
|
詳細(xì)
|
| Tofacitinib Impurity 78 |
托法替尼中間體VI |
1206875-41-3 |
詳細(xì)
|
| Lidocaine EP Impurity C |
利多卡因雜質(zhì)D |
7728-40-7 |
詳細(xì)
|
| Lidocaine EP Impurity H |
2,6-二甲基氯代乙酰苯胺 |
1131-01-7 |
詳細(xì)
|
| Dapagliflozin Hydroperoxide Impurity |
達(dá)格列凈雜質(zhì)41 |
2452300-94-4 |
詳細(xì)
|
| Tofacitinib Impurity 93 |
托法替尼雜質(zhì)93 |
|
詳細(xì)
|
| Tofacitinib Impurity 89 |
托法替尼雜質(zhì)89 |
|
詳細(xì)
|
| Tofacitinib Impurity 90 |
托法替尼雜質(zhì)90 |
|
詳細(xì)
|
| Tofacitinib Impurity 94 |
托法替尼雜質(zhì)94 |
|
詳細(xì)
|
| Tofacitinib Impurity 95 |
托法替尼雜質(zhì)95 |
|
詳細(xì)
|
| Tofacitinib Impurity 96 |
托法替尼雜質(zhì)24 |
2028267-73-2 |
詳細(xì)
|
| Tofacitinib Impurity 97 |
|
|
詳細(xì)
|
| Tofacitinib Impurity 98 |
托法替尼雜質(zhì)98 |
|
詳細(xì)
|
| Tofacitinib Impurity 99 |
托法替尼雜質(zhì) |
2227199-31-5 |
詳細(xì)
|
| Cefixime EP Impurity C |
頭孢克肟雜質(zhì)C |
|
詳細(xì)
|
| Tofacitinib Impurity B |
(3S,4R)-4-甲基-3-(甲基-7H-吡咯并[2,3-D]嘧啶-4-氨基)-BETA-氧代-1-哌啶丙腈 |
1092578-48-7 |
詳細(xì)
|
| Tofacitinib Impurity C(Citrate) |
3-[(3S,4S)-4-methyl-3-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile |
2174011-55-1 |
詳細(xì)
|
| Tofacitinib Impurity 17 |
托法替尼氫化雜質(zhì) |
1812890-23-5 |
詳細(xì)
|
| Tofacitinib Impurity 114 |
Tofacitinib Impurity 114 |
|
詳細(xì)
|
| Tofacitinib |
托法替尼 |
477600-75-2 |
詳細(xì)
|
| Tofacitinib Citrate |
枸櫞酸托法替尼 |
540737-29-9 |
詳細(xì)
|
| Tofacitinib Impurity A |
(3R,4S)-4-甲基-3-(甲基-7H-吡咯并[2,3-D]嘧啶-4-氨基)-BETA-氧代-1-哌啶丙腈 |
1092578-46-5 |
詳細(xì)
|
| Tofacitinib Impurity L |
托法替尼雜質(zhì) |
477600-76-3 |
詳細(xì)
|
| Tofacitinib Impurity N |
托法替尼雜質(zhì) 6 |
1640972-35-5 |
詳細(xì)
|
| Tofacitinib Impurity P |
Tofacitinib Impurity K |
2328165-36-0 |
詳細(xì)
|
| Tofacitinib Impurity 1 |
4-氯-7-甲苯磺酰基-7H-吡咯[2,3-D]嘧啶 |
479633-63-1 |
詳細(xì)
|
| Tofacitinib Impurity S |
托伐替尼雜質(zhì)S |
|
詳細(xì)
|
| Tofacitinib Impurity K |
托法替尼雜質(zhì) |
2227197-38-6 |
詳細(xì)
|
| Tofacitinib Impurity I |
托法替尼雜質(zhì)I (3S,4S) |
|
詳細(xì)
|
| Tofacitinib Impurity J |
枸櫞酸托法替布H039-M2-I2 |
2097982-05-1 |
詳細(xì)
|
| Tofacitinib Impurity T |
托伐替尼雜質(zhì)T |
|
詳細(xì)
|
| Tofacitinib Impurity U |
托伐替尼雜質(zhì)U |
|
詳細(xì)
|
| Tofacitinib Impurity V |
托法替尼雜質(zhì)V |
|
詳細(xì)
|
| Tofacitinib Impurity W |
托法替尼雜質(zhì)W |
|
詳細(xì)
|
| Tofacitinib Impurity X |
托法替尼雜質(zhì)X |
|
詳細(xì)
|
| Tofacitinib Impurity 3 |
Tofacitinib Impurity 3 |
1206825-36-6 |
詳細(xì)
|
| Tofacitinib Impurity 4 |
N-甲基-N-((3R,4R)-4-甲基-1-芐基-3-哌啶基)-7-((4-甲基苯基)磺酰基)7H-吡咯并[2,3-D]嘧啶-4-胺 |
923036-30-0 |
詳細(xì)
|
| Tofacitinib Impurity 76 |
(4-甲基吡啶-3-基)氨基甲酸甲酯 |
694495-63-1 |
詳細(xì)
|
| Tofacitinib Impurity H |
托法替尼雜質(zhì)H (3S,4S) |
|
詳細(xì)
|
| Tofacitinib Impurity G |
托法替尼雜質(zhì) |
1616761-00-2 |
詳細(xì)
|